Experts: FDA's Made 'Laudable' Progress, But Efforts Fall Short
This article was originally published in Scrip
While the FDA has made "extensive, transformative and laudable" progress since a scathing 2007 report by a subcommittee of the agency's Science Board condemned regulators for failing to fulfill their mission because of a weak scientific base and lack of scientific workforce, the same panel of outside expert advisers in a new analysis, unveiled on Sept. 18, identified a number of areas in which improvements continue to be needed.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.